Ainura Baibadilova
Research Subjects
Ainura Baibadilova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Aigul Bazarbayeva
Scientific Centre of Pediatric and Pediatric Surgery, Al-Farabi Avenue 146, Almaty 050060, Kazakhstan
1 shared publication - Gaukhar Nurzhanova
Scientific Centre of Pediatric and Pediatric Surgery, Al-Farabi Avenue 146, Almaty 050060, Kazakhstan
1 shared publication - Gulnara Abdilova
«Scientific Center of Pediatrics and Pediatric Surgery» JSC
1 shared publication - Ildar Fakhradiyev
Department of Medicine, S.D. Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan
1 shared publication - Timur Saliev
Institute for Fundamental and Applied Medical Research, S.D. Asfendiyarov Kazakh National Medical University, Tole Bi Street 94, Almaty 050000, Kazakhstan
1 shared publication - Zaure Dushimova
Department of Fundamental Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 27 January 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 165
Pharmacogenomics of Antineoplastic Therapy in Children: Genetic Determinants of Toxicity and Efficacy
Over the past decades, remarkable progress in multimodal therapy has significantly improved survival outcomes for children with cancer. Yet, considerable variability in treatment response and toxicity persists, often driven by underlying genetic differences that affect the pharmacokinetics and pharmacodynamics of anticancer drugs. Pharmacogenomics, the study of genetic determinants of drug response, offers a powerful approach to personalize pediatric cancer therapy by optimizing efficacy while minimizing adverse effects. This review synthesizes current evidence on key pharmacogenetic variants influencing the response to major classes of antineoplastic agents used in children, including thiopurines, methotrexate, anthracyclines, alkylating agents, vinca alkaloids, and platinum compounds. Established gene–drug associations such as TPMT, NUDT15, DPYD, SLC28A3, and RARG are discussed alongside emerging biomarkers identified through genome-wide and multi-omics studies. The review also examines the major challenges that impede clinical implementation, including infrastructural limitations, cost constraints, population-specific variability, and ethical considerations. Furthermore, it highlights how integrative multi-omics, systems pharmacology, and artificial intelligence may accelerate the translation of pharmacogenomic data into clinical decision-making. The integration of pharmacogenomic testing into pediatric oncology protocols has the potential to transform cancer care by improving drug safety, enhancing treatment precision, and paving the way toward ethically grounded, personalized therapy for children.
- 27 January 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 165
Open AccessPharmacogenomics of Antineoplastic Therapy in Children: Genetic Determinants of Toxicity and Efficacy
Over the past decades, remarkable progress in multimodal therapy has significantly improved survival outcomes for children with cancer. Yet, considerable variability in treatment response and toxicity persists, often driven by underlying genetic differences that affect the pharmacokinetics and pharmacodynamics of anticancer drugs. Pharmacogenomics, the study of genetic determinants of drug response, offers a powerful approach to personalize pediatric cancer therapy by optimizing efficacy while minimizing adverse effects. This review synthesizes current evidence on key pharmacogenetic variants influencing the response to major classes of antineoplastic agents used in children, including thiopurines, methotrexate, anthracyclines, alkylating agents, vinca alkaloids, and platinum compounds. Established gene–drug associations such as TPMT, NUDT15, DPYD, SLC28A3, and RARG are discussed alongside emerging biomarkers identified through genome-wide and multi-omics studies. The review also examines the major challenges that impede clinical implementation, including infrastructural limitations, cost constraints, population-specific variability, and ethical considerations. Furthermore, it highlights how integrative multi-omics, systems pharmacology, and artificial intelligence may accelerate the translation of pharmacogenomic data into clinical decision-making. The integration of pharmacogenomic testing into pediatric oncology protocols has the potential to transform cancer care by improving drug safety, enhancing treatment precision, and paving the way toward ethically grounded, personalized therapy for children.